← Back
Data updated: Jun 28, 2026
SQUARE PHARMS PLC
Generics Pharmaceuticals
SQUARE PHARMS PLC is a generic drug manufacturer with 4 FDA-approved products.
2017
Since
4
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
SQUARE PHARMS PLC's Key Drugs
SQUARE PHARMS PLC's core commercial portfolio centers on CALCIUM CHLORIDE 10% — its most strategically important drugs approved in the last 15 years.
SQUARE PHARMS PLC's Recent FDA Approvals
New NDA/BLA approvals for SQUARE PHARMS PLC over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
SQUARE PHARMS PLC's Therapeutic Areas
Disease areas where SQUARE PHARMS PLC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
SQUARE PHARMS PLC Pipeline Snapshot
Active clinical trials for SQUARE PHARMS PLC across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • CALCIUM CHLORIDE 10% leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2017-06-01
- Latest
- 2025-09-29
- Applications
- 4